291 related articles for article (PubMed ID: 15389792)
1. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
4. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine.
Marshall DJ; San Mateo LR; Rudnick KA; McCarthy SG; Harris MC; McCauley C; Schantz A; Geng D; Cawood P; Snyder LA
Cancer Immunol Immunother; 2005 Nov; 54(11):1082-94. PubMed ID: 16047142
[TBL] [Abstract][Full Text] [Related]
5. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
Kim JJ; Trivedi NN; Wilson DM; Mahalingam S; Morrison L; Tsai A; Chattergoon MA; Dang K; Patel M; Ahn L; Boyer JD; Chalian AA; Schoemaker H; Kieber-Emmons T; Agadjanyan MA; Weiner DB
Oncogene; 1998 Dec; 17(24):3125-35. PubMed ID: 9872328
[TBL] [Abstract][Full Text] [Related]
6. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
7. Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.
Pavlenko M; Leder C; Roos AK; Levitsky V; Pisa P
Prostate; 2005 Jun; 64(1):50-9. PubMed ID: 15651071
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
Roos AK; Moreno S; Leder C; Pavlenko M; King A; Pisa P
Mol Ther; 2006 Feb; 13(2):320-7. PubMed ID: 16185933
[TBL] [Abstract][Full Text] [Related]
9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
11. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
[TBL] [Abstract][Full Text] [Related]
12. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants.
Kim JJ; Yang JS; Dang K; Manson KH; Weiner DB
Clin Cancer Res; 2001 Mar; 7(3 Suppl):882s-889s. PubMed ID: 11300487
[TBL] [Abstract][Full Text] [Related]
13. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccination for prostate cancer.
Roos AK; King A; Pisa P
Methods Mol Biol; 2008; 423():463-72. PubMed ID: 18370222
[TBL] [Abstract][Full Text] [Related]
15. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ
Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine.
Marshall DJ; Rudnick KA; McCarthy SG; Mateo LR; Harris MC; McCauley C; Snyder LA
Vaccine; 2006 Jan; 24(3):244-53. PubMed ID: 16135392
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene.
Zhang X; Divangahi M; Ngai P; Santosuosso M; Millar J; Zganiacz A; Wang J; Bramson J; Xing Z
Vaccine; 2007 Jan; 25(7):1342-52. PubMed ID: 17052817
[TBL] [Abstract][Full Text] [Related]
19. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
20. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
